Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Phase 3

Recruiting

Conditions: Refractory Breast Carcinoma
Breast Cancer

Interventions: Other: Organoid-guided personalized treatment
Drug: Gemcitabine
Drug: Capecitabine
Drug: Vinorelbine
Drug: Eribulin

First Posted Date: 2024-02-20

Last Posted Date: 2024-02-20

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 302

Registration Number: NCT06268652

Locations: 🇨🇳
Yanxia Shi, Guangzhou, None Selected, China

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

Phase 2

Recruiting

Conditions: Rectal Adenocarcinoma

Interventions: Drug: Adebrelimab
Drug: Oxaliplatin
Drug: Capecitabine
Radiation: Short-course Radiation
Procedure: Biopsy

First Posted Date: 2024-02-20

Last Posted Date: 2024-02-20

Lead Sponsor: Sir Run Run Shaw Hospital

Target Recruit Count: 30

Registration Number: NCT06266832

Locations: 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 2

Active, not recruiting

Conditions: Gastric Cancer

Interventions: Drug: ONO-4578
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Nivolumab
Drug: S-1
Drug: Placebo

First Posted Date: 2024-02-13

Last Posted Date: 2024-07-29

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 210

Registration Number: NCT06256328

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of

and more 60 locations

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: [68Ga]Ga-NeoB
Drug: [177Lu]Lu-NeoB
Drug: Capecitabine

First Posted Date: 2024-02-08

Last Posted Date: 2024-11-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 58

Registration Number: NCT06247995

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain

The Therapeutic Effect of Different Doses of Capecitabine

Not Applicable

Completed

Conditions: Capecitabine

Interventions: Drug: capecitabine

First Posted Date: 2024-02-07

Last Posted Date: 2024-02-07

Lead Sponsor: Jingjiang People's Hospital

Target Recruit Count: 150

Registration Number: NCT06246461

Locations: 🇨🇳
Clinical effect analysis of different regimens of capecitabine in the treatment of patients with advanced colon cancer, Jingjiang, Jiangsu, China

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Pembrolizumab
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Olaparib
Drug: Capecitabine

First Posted Date: 2024-02-07

Last Posted Date: 2024-05-08

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 30

Registration Number: NCT06245889

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Phase 3

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: PD-1 blocking antibody
Drug: Gemcitabine
Drug: Cisplatin (80 mg/m2)
Radiation: Reduced-dose Intensity-modulated radiotherapy
Radiation: Conventional-dose Intensity-modulated radiotherapy
Drug: Cisplatin (100 mg/m2)
Drug: Capecitabine

First Posted Date: 2024-02-02

Last Posted Date: 2024-04-26

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 593

Registration Number: NCT06239727

Locations: 🇨🇳
Zhongshan city Peaple's Hospital, Zhongshan, Guangdong, China
🇨🇳
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China

and more 5 locations